Jeanmougin M, Manciet J R, Moulin J P, Civatte J
Unité de photodermatologie, Hôpital Saint-Louis, Paris.
Allerg Immunol (Paris). 1989 May;21(5):205-7.
Solar urticaria is a rare photodermatosis, but it is extremely incapacitating and therapy is usually ineffective. Three patients who took a daily dose of 240 mg terfenadine were able to be normally exposed to sunlight. This efficacy was confirmed by photobiological tests. The minimal dose necessary to induce urticaria was increased at least three times. These results confirming recently published ones. Terfenadine at 240 mg per day seems to be the treatment of choice for solar urticaria because of its efficacy and excellent tolerance-especially as there is no sedative effect.
日光性荨麻疹是一种罕见的光皮肤病，但它极具致残性，且治疗通常无效。三名每日服用240毫克特非那定的患者能够正常暴露于阳光下。这种疗效通过光生物学测试得到了证实。诱发荨麻疹所需的最小剂量至少增加了三倍。这些结果证实了最近发表的研究结果。由于其疗效和良好的耐受性，尤其是没有镇静作用，每天240毫克的特非那定似乎是日光性荨麻疹的首选治疗方法。
